Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| Immunostimulants drugs | 21 | 0.24 [0.10; 0.56], 1 RCT, I2=0%
unassessable degree of certainty | - | 0.39 [0.14; 1.08], 9 RCTs, I2=22%
inconclusive result | 1.08 [0.45; 2.60], 2 RCTs, I2=72%
inconclusive result | |
| anti-inflammatory therapies | 2 | - | - | 0.55 [0.19; 1.54], 2 RCTs, I2=0%
inconclusive result | - | |
| corticosteroids | 2 | - | - | 0.98 [0.06; 15.76], 2 RCTs, I2=0%
inconclusive result | - | |
| inhaled corticosteroids | 2 | 0.16 [0.03; 0.74], 1 RCT, I2=0% demonstrated
unassessable degree of certainty | 1.21 [1.08; 1.36], 2 RCTs, I2=0% demonstrated
moderate degree of certainty | - | - | |
| Apilimod | 0 | - | - | - | - | |
| Immunosuppressants drugs | 0 | - | - | - | - | |
| Kinase inhibitors | 0 | - | - | - | - | |
| leflunomide | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| statins | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
